Although CDK4/6 inhibitors have ample BBB penetration, their retention is limited by efflux through ABCB1 and P-gp transporters [11, 12]; hence, clinical trials for glioblastoma have been unsuccessful [13]. The gene discussed is CDK4; the disease is glioblastoma.